{"id":70789,"date":"2026-05-12T11:08:40","date_gmt":"2026-05-12T11:08:40","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70789"},"modified":"2026-10-15T10:33:57","modified_gmt":"2026-10-15T10:33:57","slug":"ahk-cu","status":"publish","type":"product","link":"https:\/\/medsbase.com\/fr\/product\/ahk-cu\/","title":{"rendered":"AHK-Cu"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">R\u00e9ponse rapide \u2014 Qu'est-ce que l'AHK-Cu ?<\/h3>\n<p style=\"margin: 0;\"><strong>AHK-Cu<\/strong> (Complexe de cuivre(II) alanyl-histidyl-lysine) est un tripeptide synth\u00e9tique liant le cuivre et la mol\u00e9cule s\u0153ur du <a href=\"https:\/\/medsbase.com\/fr\/ghk-cu\/\">GHK-Cu<\/a>. While GHK-Cu is the canonical skin and wound-healing copper peptide, AHK-Cu&#8217;s signal is concentrated in <strong>biologie du follicule pileux<\/strong> \u2014 published preclinical work documents stimulation of dermal papilla cells, follicular enlargement, increased follicular vascularization, and prolongation of the anagen growth phase. Supplied in 20\u00a0mg and 50\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Ce que vous obtenez avec MedsBase :<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/fr\/reviews\/\">avis clients<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Chaque commande est couverte par notre <a href=\"https:\/\/medsbase.com\/fr\/medsbase-re-shipment-assurance-policy\/\"><strong>Politique de R\u00e9exp\u00e9ditions Garanties<\/strong><\/a> \u2014 si votre colis n'arrive pas dans les 20 jours ouvrables, nous le r\u00e9exp\u00e9dions.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Sp\u00e9cification<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">D\u00e9tail<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Num\u00e9ro CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">110374-12-4 (AHK-Cu) ; 71567-06-1 (peptide libre AHK)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Formule mol\u00e9culaire<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>15<\/sub>H<sub>25<\/sub>CuN<sub>6<\/sub>O<sub>4<\/sub> (Complexe cuivre 1:1)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Masse mol\u00e9culaire<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~417 Da (complexe cuivreux)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>S\u00e9quence<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Ala-His-Lys (AHK, 3 acides amin\u00e9s) coordonn\u00e9s \u00e0 un seul ion Cu<sup>2+<\/sup> via l'azote imidazole de l'His, l'extr\u00e9mit\u00e9 amine de l'Ala et l'azote peptidique d\u00e9proton\u00e9 entre l'Ala et l'His<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forme<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Complexe cuivre-peptide lyophilis\u00e9 (poudre bleue \u00e0 bleu-violet ; la couleur provient des transitions d-d du Cu li\u00e9<sup>2+<\/sup>)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Puret\u00e9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599 % (v\u00e9rifi\u00e9 par HPLC, COA sur demande)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Stockage<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilis\u00e9 : 2\u20138 \u00b0C (r\u00e9frig\u00e9rateur) pour le stock de travail ; \u221220 \u00b0C pour le stockage \u00e0 long terme des flacons non ouverts. Reconstitu\u00e9 : 2\u20138 \u00b0C, \u00e0 utiliser dans ~30 jours. Prot\u00e9ger de la lumi\u00e8re. Ne pas congeler-d\u00e9congeler la solution reconstitu\u00e9e.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilit\u00e9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Eau bact\u00e9riostatique (recommand\u00e9e) ou eau st\u00e9rile pour des fen\u00eatres d'utilisation plus courtes. Soluble dans l'eau ; la solution dissoute conserve la couleur bleue caract\u00e9ristique du Cu li\u00e9<sup>2+<\/sup>.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Qu'est-ce que l'AHK-Cu ?<\/h2>\n<p><strong>AHK-Cu<\/strong> (Complexe cuivre(II) d'alanyl-histidyl-lysine) est un tripeptide synth\u00e9tique liant le cuivre, compos\u00e9 des trois acides amin\u00e9s Ala, His et Lys, coordonn\u00e9 \u00e0 un seul ion Cu<sup>2+<\/sup> ion. C'est la mol\u00e9cule s\u0153ur de celle qui a \u00e9t\u00e9 plus largement \u00e9tudi\u00e9e <a href=\"https:\/\/medsbase.com\/fr\/ghk-cu\/\">GHK-Cu<\/a> \u2014 both belong to the &#8220;copper peptide&#8221; class, both share the same Cu-coordination architecture using a histidine residue, and both are studied in dermatological contexts. Where they diverge is in primary signal: GHK-Cu is the canonical peptide for skin remodelling, wound healing, and connective-tissue repair, while AHK-Cu&#8217;s most-cited applications are in <strong>biologie du follicule pileux<\/strong>. The well-characterised molecular composition is C<sub>15<\/sub>H<sub>25<\/sub>CuN<sub>6<\/sub>O<sub>4<\/sub>, masse mol\u00e9culaire environ 417 Da. L'ion Cu<sup>2+<\/sup> ion coordinates with the tripeptide via the imidazole nitrogen of histidine, the amino terminus of alanine, and the deprotonated peptide nitrogen between Ala and His \u2014 the same square-planar coordination geometry as in GHK-Cu. The bound copper gives both compounds their characteristic blue-to-violet colour in solid and dissolved form \u2014 users reconstituting AHK-Cu should expect a visibly blue working solution. AHK-Cu is supplied as a high-purity lyophilized copper-peptide complex for reconstitution with bacteriostatic water. The compound is <strong>non approuv\u00e9<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. For the sister skin-studies copper peptide, see our <a href=\"https:\/\/medsbase.com\/fr\/ghk-cu\/\">GHK-Cu<\/a> page produit. <\/p>\n<h2>M\u00e9canisme d'action \u2014 Apport de cuivre aux cellules papillaire du follicule pileux<\/h2>\n<p>Ce qui distingue m\u00e9caniquement l'AHK-Cu parmi les peptides de cuivre est sa <strong>signalisation pr\u00e9f\u00e9rentielle vers les cellules papillaire dermiques<\/strong> in the hair follicle \u2014 the mesenchymal cells at the base of each follicle that regulate hair-shaft production and cycle through the growth (anagen), regression (catagen), and rest (telogen) phases. Published studies has documented three principal mechanisms:<\/p>\n<ul>\n<li><strong>Apport de cuivre aux cellules papillaire dermiques<\/strong> \u2014 L'ion Cu<sup>2+<\/sup> ion is the active payload of AHK-Cu (and of GHK-Cu in skin studies). The tripeptide is a vehicle that ferries the metal ion into target tissue, where copper participates in multiple enzyme cofactor roles including lysyl oxidase (collagen and elastin cross-linking) and superoxide dismutase (oxidative-stress buffering). At the hair follicle, dermal papilla cells take up copper from AHK-Cu and use it to support the follicular extracellular matrix and oxidative-stress management that anagen requires.<\/li>\n<li><strong>Augmentation du VEGF et vascularisation folliculaire<\/strong> \u2014 L'AHK-Cu stimule l'expression du facteur de croissance endoth\u00e9lial vasculaire (VEGF) dans les cellules papillaire dermiques. L'effet en aval est une augmentation de la perfusion folliculaire \u2014 croissance de nouveaux capillaires \u00e0 la base du follicule qui soutient les demandes m\u00e9taboliques des k\u00e9ratinocytes de la matrice pilaire en prolif\u00e9ration rapide pendant l'anag\u00e8ne. Ce m\u00e9canisme d'am\u00e9lioration de la perfusion recoupe celui du minoxidil mais op\u00e8re via une voie fondamentalement diff\u00e9rente (signalisation directe par peptide de cuivre plut\u00f4t que modulation des canaux potassiques sensibles \u00e0 l'ATP).<\/li>\n<li><strong>Prolongation de la phase anag\u00e8ne et augmentation de la taille folliculaire<\/strong> \u2014 In published rodent hair-cycle studies, AHK-Cu administration prolongs the duration of the anagen growth phase and increases overall follicular size. The combined effect is more hair-shaft production per follicle per cycle. The mechanism appears to be downstream of the copper-delivery and VEGF-upregulation steps \u2014 healthy, well-perfused follicles in a copper-replete environment sustain anagen for longer before transitioning to catagen.<\/li>\n<\/ul>\n<p>The mechanism is fundamentally different from the two FDA-approved hair-loss compounds: finasteride blocks 5-alpha-reductase to lower scalp DHT (hormonal mechanism); minoxidil opens ATP-sensitive potassium channels to vasodilate follicular vessels (vascular mechanism). AHK-Cu provides direct mesenchymal-cell signalling and copper-cofactor delivery, working at a different point in follicular biology than either FDA-approved compound \u2014 which makes it a useful tool for dissecting follicular cell biology independent of androgen-axis or vasodilation-mediated mechanisms. Subcutaneous, topical, and intrafollicular injection routes are all documented in published studies. <\/p>\n<h2>Published Evidence<\/h2>\n<p>AHK-Cu is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Hair follicle biology studies<\/strong> \u2014 dermal papilla cell proliferation assays, follicular size measurement, hair-shaft diameter analysis, organ-cultured hair follicle studies; canonical copper-peptide compound for the hair-axis (Pyo et al., J Korean Med Sci 2007; Uno &amp; Kurata, J Investig Dermatol)<\/li>\n<li><strong>Hair cycle studies<\/strong> \u2014 dur\u00e9e des phases anag\u00e8ne\/catag\u00e8ne\/t\u00e9log\u00e8ne, induction de l'anag\u00e8ne dans les follicules en t\u00e9log\u00e8ne, r\u00e9ponse dose-effet comparative avec des compos\u00e9s comparateurs \u00e9tablis pour l'axe capillaire<\/li>\n<li><strong>Follicular vascularization studies<\/strong> \u2014 expression du VEGF, densit\u00e9 capillaire \u00e0 la base du follicule, mesure de la perfusion p\u00e9ri-folliculaire<\/li>\n<li><strong>Comparative copper peptide studies<\/strong> \u2014 comparaison directe avec <a href=\"https:\/\/medsbase.com\/fr\/ghk-cu\/\">GHK-Cu<\/a> for dermatological studies; AHK-Cu favoured for hair-axis endpoints, GHK-Cu favoured for skin\/wound\/anti-aging endpoints<\/li>\n<li><strong>Topical and intradermal formulation studies<\/strong> \u2014 AHK-Cu is one of the more-studied copper peptides for topical and intradermal delivery; published studies investigates skin-penetration depth, follicular targeting via different vehicle formulations<\/li>\n<li><strong>Dissection des m\u00e9canismes de la perte de cheveux<\/strong> \u2014 alongside finasteride (androgen-axis) and minoxidil (vascular axis), AHK-Cu provides a third orthogonal studies mechanism (mesenchymal-cell + copper-cofactor + VEGF axis); useful for mechanism-of-action studies designs<\/li>\n<li><strong>Collagen and elastin studies<\/strong> \u2014 copper&#8217;s role as cofactor for lysyl oxidase makes copper peptides relevant to studies on extracellular matrix crosslinking; AHK-Cu shares this mechanism with GHK-Cu at the broader level although hair-axis effects predominate.<\/li>\n<\/ul>\n<p>For broader context on where AHK-Cu fits within the copper-peptide and dermatological studies landscape, see <a href=\"https:\/\/medsbase.com\/fr\/ghk-cu\/\">GHK-Cu<\/a> as the canonical skin-studies copper peptide, <a href=\"https:\/\/medsbase.com\/fr\/bpc-157\/\">BPC-157<\/a> for tissue-repair studies, and <a href=\"https:\/\/medsbase.com\/fr\/tb-500\/\">TB-500<\/a> for systemic recovery. Browse the full <a href=\"https:\/\/medsbase.com\/fr\/peptides\/\">catalogue de peptides<\/a> pour les compos\u00e9s associ\u00e9s. <\/p>\n<h2>Forces et concentrations disponibles<\/h2>\n<p>MedsBase stocks AHK-Cu in two lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Concentration du flacon<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Cas d'utilisation typique<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tailles de conditionnement<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>20\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 topical formulation and short-cycle protocols<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>50\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Bulk packs vial, extended cycles, lowest per-mg cost, multi-cohort follicle studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Both strengths are the same chemical form (lyophilized copper-peptide complex, 99%+ HPLC purity). Higher-mg vials are particularly useful for AHK-Cu because of the relatively large doses typical in topical-formulation studies compared with the microgram-range systemic peptides. Higher-mg vials require smaller reconstitution volumes per unit dose. <\/p>\n<h2>Comparaison \u2014 AHK-Cu vs GHK-Cu<\/h2>\n<p>AHK-Cu et <a href=\"https:\/\/medsbase.com\/fr\/ghk-cu\/\">GHK-Cu<\/a> are sister copper-binding tripeptides that share the same Cu-coordination chemistry but differ in the first amino-acid residue (Ala vs Gly). This minor structural difference produces qualitatively different signals: GHK-Cu dominates skin\/wound\/anti-aging studies while AHK-Cu&#8217;s strongest signal is in hair follicle biology. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e8re<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">AHK-Cu<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">GHK-Cu<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Longueur<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">3 acides amin\u00e9s (tripeptide)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">3 acides amin\u00e9s (tripeptide)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>S\u00e9quence<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ala-His-Lys<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Gly-His-Lys<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Coordination du cuivre<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">1:1 Cu<sup>2+<\/sup> via His + N-terminal<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">1:1 Cu<sup>2+<\/sup> via His + N-terminal<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Primary signal<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Biologie du follicule pileux, prolongation de la phase anag\u00e8ne<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Remodelage cutan\u00e9, cicatrisation, anti-\u00e2ge<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Type de cellule cible<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Cellules de la papille dermique (follicule pileux)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Fibroblastes dermiques, k\u00e9ratinocytes (peau)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Signalisation VEGF<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Fort \u2014 vascularisation folliculaire<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Mod\u00e9r\u00e9 \u2014 angiogen\u00e8se du lit de la plaie<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Occurrence endog\u00e8ne<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Synth\u00e9tique (pas de pool endog\u00e8ne significatif)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Endog\u00e8ne (diminue avec l'\u00e2ge dans le plasma)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dose typique<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">2\u201310 mg topique \/ 1\u20135 mg sous-cutan\u00e9<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">1\u20135 mg topique \/ 0,5\u20132 mg sous-cutan\u00e9<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For hair-axis studies, AHK-Cu is the canonical first choice because of the dermal-papilla-cell selectivity and the documented anagen-prolongation signal. For skin remodelling, wound healing, and anti-aging studies, <a href=\"https:\/\/medsbase.com\/fr\/ghk-cu\/\">GHK-Cu<\/a> is the canonical reference. Some studies designs use both in parallel arms to dissect copper-peptide effects that are shared (general Cu cofactor delivery) from effects that are sequence-specific (cell-type selectivity). <\/p>\n<h2>Stockage et reconstitution<\/h2>\n<p><strong>Avant la reconstitution :<\/strong> conserver les flacons lyophilis\u00e9s r\u00e9frig\u00e9r\u00e9s \u00e0 2\u20138 \u00b0C dans leur emballage d'origine pour le stock de travail \u00e0 court terme. Pour le stockage \u00e0 long terme non ouvert, congeler \u00e0 \u221220 \u00b0C. L'AHK-Cu lyophilis\u00e9 est stable sous r\u00e9frig\u00e9ration jusqu'\u00e0 24 mois et \u00e0 \u221220 \u00b0C jusqu'\u00e0 36 mois. \u00c9viter les cycles de cong\u00e9lation-d\u00e9cong\u00e9lation de la poudre lyophilis\u00e9e. La<sup>2+<\/sup> coordination du Cu est stable sous forme lyophilis\u00e9e ; une fois reconstitu\u00e9, une exposition prolong\u00e9e \u00e0 la lumi\u00e8re ou \u00e0 des agents r\u00e9ducteurs peut affecter l'\u00e9tat d'oxydation du cuivre. <strong>Proc\u00e9dure de reconstitution :<\/strong> injecter de l'eau bact\u00e9riostatique le long de la paroi du flacon de peptide (pas directement sur le g\u00e2teau lyophilis\u00e9). Pour un flacon de 20 mg, 2,0 mL d'eau bact\u00e9riostatique donnent une concentration de travail de 10 mg\/mL \u2014 0,1 mL d\u00e9livre 1 mg ; 0,5 mL d\u00e9livre 5 mg. Agiter doucement \u2014 ne pas <strong>re\u00e7oit pas<\/strong> secouer \u2014 et laisser 2 \u00e0 5 minutes pour une dissolution compl\u00e8te. Une solution correctement reconstitu\u00e9e doit \u00eatre claire avec la couleur bleue caract\u00e9ristique du Cu li\u00e9.<sup>2+<\/sup>. Une turbidit\u00e9 ou un pr\u00e9cipit\u00e9 indique un probl\u00e8me de reconstitution ; jeter et recommencer. <strong>Apr\u00e8s reconstitution :<\/strong> store refrigerated at 2\u20138\u00a0\u00b0C and use within 30 days for optimal stability. Do not freeze the reconstituted solution \u2014 freeze-thaw cycles degrade peptide integrity. Protect from direct light at all times. For topical formulation studies, AHK-Cu can be incorporated into a wide range of vehicles (creams, gels, serums) for follicle-studies delivery; published vehicle studies includes liposomal and microemulsion formulations for enhanced follicular penetration. <\/p>\n<h2 id=\"faqs\">Questions fr\u00e9quemment pos\u00e9es<\/h2>\n<h3>What is AHK-Cu used for in studies?<\/h3>\n<p>AHK-Cu is used in studies investigating hair follicle biology, dermal papilla cell proliferation, anagen phase prolongation, follicular vascularization, hair-shaft diameter, comparative copper-peptide pharmacology, topical and intradermal formulation studies, and mechanism-of-action dissection of hair-loss biology distinct from the androgen-axis (finasteride) and vascular (minoxidil) mechanisms. It is the canonical copper-peptide compound for the hair-axis. The pharmaceutical-grade AHK-Cu sold here is <strong>re\u00e7oit pas<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>En quoi l'AHK-Cu diff\u00e8re-t-il du GHK-Cu ?<\/h3>\n<p>Les deux sont des tripeptides liant le cuivre qui partagent la m\u00eame architecture de coordination du Cu (His-m\u00e9di\u00e9e 1:1 Cu<sup>2+<\/sup> binding). They differ in the first amino-acid residue \u2014 alanine in AHK-Cu, glycine in GHK-Cu \u2014 producing different cell-type selectivity in published studies. AHK-Cu&#8217;s strongest signal is in dermal papilla cells of the hair follicle; <a href=\"https:\/\/medsbase.com\/fr\/ghk-cu\/\">GHK-Cu<\/a>\u2018Le signal le plus fort de \u2018s est observ\u00e9 dans les fibroblastes cutan\u00e9s et les k\u00e9ratinocytes. Ces deux types cellulaires sont souvent \u00e9tudi\u00e9s en parall\u00e8le pour distinguer les effets partag\u00e9s des peptides de cuivre des effets sp\u00e9cifiques \u00e0 la s\u00e9quence. <\/p>\n<h3>What is the typical AHK-Cu dose?<\/h3>\n<p>Published preclinical protocols typically use 1\u20135\u00a0mg per administration for subcutaneous delivery and 2\u201310\u00a0mg for topical formulation studies, given 1\u20133 times daily for 4\u201312 week cycles. A 20\u00a0mg vial reconstituted with 2.0\u00a0mL bacteriostatic water yields 10\u00a0mg\/mL \u2014 0.1\u00a0mL equals 1\u00a0mg, 0.5\u00a0mL equals 5\u00a0mg. <\/p>\n<h3>Non. L'AHK-Cu n'est approuv\u00e9 ni par la FDA, ni par l'EMA, ni par la MHRA, ni par aucun autre grand r\u00e9gulateur pour un usage th\u00e9rapeutique humain. Des peptides cuivr\u00e9s ont \u00e9t\u00e9 incorpor\u00e9s dans certains produits cosm\u00e9tiques sous des cadres r\u00e9glementaires cosm\u00e9tiques, mais l'AHK-Cu sp\u00e9cifiquement n'a aucune approbation th\u00e9rapeutique. Tout AHK-Cu vendu par des fournisseurs r\u00e9serv\u00e9s \u00e0 la recherche est destin\u00e9 \u00e0 des investigations en laboratoire et ne doit pas \u00eatre administr\u00e9 \u00e0 des humains.<\/h3>\n<p>No. AHK-Cu is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. Copper peptides have been incorporated into some cosmetic products under cosmetic-regulation frameworks, but AHK-Cu specifically has no therapeutic approval. <\/p>\n<h3>Flacons lyophilis\u00e9s : r\u00e9frig\u00e9r\u00e9s \u00e0 2\u20138 \u00b0C pour le stock de travail \u00e0 court terme, ou \u00e0 \u221220 \u00b0C pour le stockage \u00e0 long terme des flacons non ouverts. Solution reconstitu\u00e9e : r\u00e9frig\u00e9r\u00e9e \u00e0 2\u20138 \u00b0C, \u00e0 utiliser dans les 30 jours. Ne pas congeler la solution reconstitu\u00e9e \u2014 les cycles de cong\u00e9lation-d\u00e9cong\u00e9lation d\u00e9gradent le peptide et peuvent affecter la coordination du cuivre. Prot\u00e9ger de la lumi\u00e8re directe en permanence pour pr\u00e9server l'\u00e9tat d'oxydation du cuivre.<\/h3>\n<p>Flacons lyophilis\u00e9s : conserv\u00e9s au r\u00e9frig\u00e9rateur \u00e0 2\u20138 \u00b0C pour un stock de travail \u00e0 court terme, ou \u00e0 \u221220 \u00b0C pour un stockage \u00e0 long terme des flacons non ouverts. Solution reconstitu\u00e9e : conserv\u00e9e au r\u00e9frig\u00e9rateur \u00e0 2\u20138 \u00b0C, \u00e0 utiliser dans les 30 jours. Ne pas congeler la solution reconstitu\u00e9e \u2014 les cycles de cong\u00e9lation-d\u00e9cong\u00e9lation d\u00e9gradent le peptide et peuvent affecter la coordination du cuivre. Prot\u00e9ger de la lumi\u00e8re directe en permanence pour pr\u00e9server l'\u00e9tat d'oxydation du cuivre. <\/p>\n<h3>Agitez doucement le flacon. Une solution correctement reconstitu\u00e9e est limpide avec la couleur bleue caract\u00e9ristique du Cu li\u00e9<\/h3>\n<p>Suivez la proc\u00e9dure de reconstitution ci-dessus. Ajoutez de l'eau bact\u00e9riostatique le long de la paroi du flacon (pas directement sur la poudre lyophilis\u00e9e), agitez doucement et laissez reposer 2 \u00e0 5 minutes pour une dissolution compl\u00e8te. Ne <strong>re\u00e7oit pas<\/strong> \u2014 la couleur elle-m\u00eame confirme une reconstitution r\u00e9ussie et une coordination intacte du cuivre. Pour un flacon de 20 mg + 2,0 mL de diluant, la concentration de travail est de 10 mg\/mL.<sup>2+<\/sup> \u2014 la couleur elle-m\u00eame confirme une reconstitution r\u00e9ussie et une coordination intacte du cuivre. Pour un flacon de 20 mg + 2,0 mL de diluant, la concentration de travail est de 10 mg\/mL. <\/p>\n<h3>Quelles sont les dosages disponibles chez MedsBase ?<\/h3>\n<p>MedsBase carries AHK-Cu in 20\u00a0mg and 50\u00a0mg lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Pourquoi l'AHK-Cu est-il de couleur bleue ?<\/h3>\n<p>La couleur caract\u00e9ristique bleue \u00e0 violette de l'AHK-Cu (et du GHK-Cu) provient des transitions \u00e9lectroniques d-d du cuivre li\u00e9<sup>2+<\/sup> dans l'environnement de coordination plan-carr\u00e9 cr\u00e9\u00e9 par le r\u00e9sidu d'histidine et le squelette peptidique. La couleur est un indicateur qualitatif utile de la coordination r\u00e9ussie du cuivre \u2014 une solution bleue correctement reconstitu\u00e9e confirme une liaison intacte du Cu<sup>2+<\/sup> , tandis qu'une solution incolore ou p\u00e2le indiquerait une perte ou une d\u00e9gradation du cuivre. Ceci est unique parmi les petits peptides \u2014 la plupart des peptides synth\u00e9tiques donnent des solutions incolores lorsqu'ils sont reconstitu\u00e9s. <\/p>\n<h3>Comment l'AHK-Cu se compare-t-il au finast\u00e9ride ou au minoxidil ?<\/h3>\n<p>The three target hair-loss biology through completely different mechanisms. Finasteride blocks 5-alpha-reductase to lower scalp dihydrotestosterone (DHT) levels \u2014 an androgen-axis mechanism. Minoxidil opens ATP-sensitive potassium channels to vasodilate follicular vessels \u2014 a vascular mechanism. AHK-Cu provides direct copper-cofactor delivery and VEGF-mediated follicular vascularization at the dermal papilla cell level \u2014 a mesenchymal-cell mechanism. The three mechanisms are orthogonal, which makes AHK-Cu a useful tool for studying follicular biology independent of androgen-axis or vasodilation-mediated effects. <\/p>\n<h3>Does AHK-Cu cause side reported effects?<\/h3>\n<p>Published preclinical studies has reported a notably clean safety profile at typical doses, with the main on-target effect being follicular stimulation. Off-target findings can include local injection-site irritation and (with prolonged high-dose topical exposure) modest cutaneous discolouration from copper deposition \u2014 both reversible with discontinuation. Systemic adverse effects from topical applications are rare due to limited transcutaneous absorption. <\/p>\n<h3>Quelle est la demi-vie de l'AHK-Cu ?<\/h3>\n<p>In preclinical studies, AHK-Cu has a relatively short plasma half-life (~1\u20132 hours) following subcutaneous administration. The short half-life is offset by retention of bound copper in target tissues \u2014 even after plasma clearance, the copper delivered to dermal papilla cells continues to support follicular biology through its enzyme-cofactor roles. Topical formulations provide sustained local exposure that is more relevant for hair-axis studies than the systemic plasma profile. <\/p>\n<h3>Can AHK-Cu and GHK-Cu be stacked in studies?<\/h3>\n<p>Yes. The two copper peptides target different cell types (dermal papilla for AHK-Cu, dermal fibroblasts for GHK-Cu) and address different studies domains (hair vs skin), so co-administration is not pharmacologically redundant. Study protocols studying combined skin-and-hair endpoints \u2014 for example, comprehensive dermatological remodelling studies \u2014 sometimes use both arms. <\/p>\n<h3>How long does AHK-Cu take to show effects in preclinical studies?<\/h3>\n<p>Acute effects on dermal papilla cell VEGF expression are detectable within 24\u201372 hours in cell-culture studies. Follicular size and anagen-prolongation effects in rodent hair-cycle models typically become statistically significant after 4\u20138 weeks of regular treatment and continue to accrue through 12\u201316 weeks \u2014 matching the natural hair-cycle timeframe. <\/p>\n<h3>Puis-je commander de l'AHK-Cu pour une livraison internationale ?<\/h3>\n<p>Oui. MedsBase exp\u00e9die l'AHK-Cu dans le monde entier via notre r\u00e9seau d\u00e9di\u00e9 \u00e0 l'exp\u00e9dition de peptides. Les commandes de peptides uniquement sont \u00e9ligibles \u00e0 notre service d'exp\u00e9dition de peptides autonome. Toutes les commandes sont exp\u00e9di\u00e9es dans un emballage \u00e0 temp\u00e9rature contr\u00f4l\u00e9e avec un suivi complet et sont couvertes par notre <a href=\"https:\/\/medsbase.com\/fr\/medsbase-re-shipment-assurance-policy\/\">Politique de R\u00e9exp\u00e9ditions Garanties<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Hair, Skin, and Tissue-Regeneration Studies<\/h2>\n<ul>\n<li><a href=\"\/fr\/ghk-cu\/\"><strong>GHK-Cu<\/strong><\/a> \u2014 Sister copper-binding tripeptide \u2014 canonical skin remodelling and wound-healing compound<\/li>\n<li><a href=\"\/fr\/bpc-157\/\"><strong>BPC-157<\/strong><\/a> \u2014 Body Protection Compound \u2014 tissue-regeneration and recovery<\/li>\n<li><a href=\"\/fr\/tb-500\/\"><strong>TB-500 (Thymosine B\u00eata-4)<\/strong><\/a> \u2014 Systemic healing fragment \u2014 tissue and vascular recovery<\/li>\n<li><a href=\"\/fr\/epitalon\/\"><strong>Epitalon<\/strong><\/a> \u2014 AEDG pineal tetrapeptide \u2014 longevity and circadian rhythm support<\/li>\n<li><a href=\"\/fr\/semax\/\"><strong>Semax<\/strong><\/a> \u2014 Nootropic heptapeptide \u2014 CNS compound<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Pour en savoir plus<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explore the copper-peptide studies landscape<\/strong><\/p>\n<p style=\"margin: 0;\">Parcourez toute la <a href=\"https:\/\/medsbase.com\/fr\/peptides\/\"><strong>catalogue de peptides<\/strong><\/a>, avec des compos\u00e9s connexes en dermatologie et en r\u00e9g\u00e9n\u00e9ration tissulaire, y compris <a href=\"https:\/\/medsbase.com\/fr\/ghk-cu\/\">GHK-Cu<\/a> (sister copper peptide for skin studies), <a href=\"https:\/\/medsbase.com\/fr\/bpc-157\/\">BPC-157<\/a> (r\u00e9g\u00e9n\u00e9ration tissulaire), et <a href=\"https:\/\/medsbase.com\/fr\/tb-500\/\">TB-500<\/a> (gu\u00e9rison syst\u00e9mique).<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Tripeptide Alanyl-Histidyl-Lysine Cuivre(II)<br \/>\n\u2705 Mol\u00e9cule s\u0153ur du GHK-Cu<br \/>\n\u2705 Hair follicle biology compound<br \/>\n\u2705 Stimulation des cellules de la papille dermique, prolongation de la phase anag\u00e8ne<br \/>\n\u2705 M\u00e9canisme orthogonal \u00e0 ceux du finast\u00e9ride\/minoxidil<\/p>\n<p><strong>AHK-Cu<\/strong> contient un complexe synth\u00e9tique de cuivre-peptide.<\/p>","protected":false},"featured_media":70940,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6290,5441],"class_list":["post-70789","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-ahk-cu","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product\/70789","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/comments?post=70789"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/media\/70940"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/media?parent=70789"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_brand?post=70789"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_cat?post=70789"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_tag?post=70789"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}